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IL-23 is an important molecular driver of Th17 cells and has strong
tumor-promoting proinflammatory activity postulated to occur via
adaptive immunity. Conversely, more recently it has been reported
that IL-17A elicits a protective inflammation that promotes the acti-
vation of tumor-specific CD8+ T cells. Here we show the much
broader impact of IL-23 in antagonizing antitumor immune
responses primarily mediated by innate immunity. Furthermore,
the majority of this impact was independent of IL-17A, which did
not appear critical for many host responses to tumor initiation or
metastases. IL-23–deficient mice were resistant to experimental
tumor metastases in three models where host NK cells controlled
disease. Immunotherapy with IL-2 was more effective in mice lack-
ing IL-23, and again the protection afforded was NK cell mediated
and independent of IL-17A. Further investigation revealed that loss
of IL-23 promoted perforin and IFN-γ antitumor effector function in
both metastasis models examined. IL-23-deficiency also strikingly
protectedmice from tumor formation in two distinctmousemodels
of carcinogenesis where the dependence on host IL-12p40 and IL-
17A was quite different. Notably, in the 3′-methylcholanthrene
(MCA) induction of fibrosarcoma model, this protection was com-
pletely lost in the absence of NK cells. Overall, these data indicate
the general role that IL-23 plays in suppressing natural or cytokine-
induced innate immunity, promoting tumor development and
metastases independently of IL-17A.
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The cytokines IL-12 and IL-23 are members of a small family ofproinflammatory heterodimeric cytokines (1). Both cytokines
share a common p40 subunit that is covalently linked to a p35
subunit to form IL-12 or to a p19 subunit to form IL-23 (2, 3).
IL-12 and IL-23 are expressed predominantly by activated den-
dritic cells (DC) and phagocytic cells, and are stimulated by
pathogens, CD40L, and TLR ligands (ref. 3; reviewed in ref. 4).
Receptor complexes are comprised of an IL-12Rβ1 subunit that is
completed with the IL-12Rβ2 subunit for IL-12, or the novel
subunit IL-23R for IL-23 (5, 6). Cellular receptor expression
reportedly includes T cells, natural killer (NK) cells, and NKT
cells, with lower levels of IL-23R complexes also found on mon-
ocytes, macrophages, and DC populations (6).
There is mounting evidence that IL-12 and IL-23 drive diver-
gent immunological pathways (reviewed in ref. 7). Whereas IL-12
leads to development of IFN-γ-producing Th1 cells and enhanced
anti-microbial and cytotoxic responses, IL-23 appears to promote
the proliferation and inflammatory function of Th17 cells (8).
IL-17-IL-17R ligation results in the release of inflammatory fac-
tors such as IL-1, IL-6, IL-8, TNF-α, prostaglandin E2, and several
chemokines to further the inflammatory cascade (9). The Th17
cell has been implicated as central to inflammatory conditions in
psoriasis, ischemic injury, inflammatory bowel disease, and auto-
immune inflammation (7, 10, 11). However, the importance of
IL-17A and Th17 cells in autoimmune diseases remains con-
troversial (12–14), as does the existence of the Th17 cell in vivo
(15). IL-23 induces chronic inflammation through the stimulation
of innate myeloid effector cells and stromal activation, whereas
the Th17 cell plays a decisive role to orchestrate inflammatory
tissue destruction. However, to date, the role of IL-17 and IL-23 in
tumor immunity is comparatively poorly understood, and it has
not been clear whether the same IL-17/IL-23 axis regulates the
tumor microenvironment.
The role of IL-23 in tumorigenesis was clearly demonstrated in
mice lacking IL-23p19 that were almost completely resistant to
7,12-dimethylbenz[a]anthracene (DMBA)/12-O-tetradecanoyl-
phorbol-13-acetate (TPA)-induced skin papilloma (16). These
studies reported a significant increase in infiltrating CD8+ T cells
in carcinogen-treated skin of IL-23p19–deficient mice [compared
with wild-type (WT) counterparts] coincident with reduced IL-17,
MMP9, and CD31 expression, and lower numbers of Gr-1+ and
CD11b+ cells. Thus the local balance of IL-12 and IL-23 in the
tumor microenvironment appeared to regulate immune surveil-
lance by cytotoxic T cells in situ. Additional experiments using
transplanted syngeneic tumors in IL-23–deficient mice supported
this view (16). Subsequently, Stat3 signaling within the tumor
microenvironment has been shown to induce IL-23, while inhib-
iting IL-12, thereby shifting the balance of tumor immunity toward
carcinogenesis. Stat3 induces expression of IL-23, which is mainly
produced by tumor-associated macrophages, via direct tran-
scriptional activation of the IL-23/p19 gene (17). Despite the clear
link between IL-23 and Th17 cells, a role for endogenous IL-17 in
tumor control has only recently been examined. Surprisingly, the
results published thus far are completely contradictory with two
studies reporting a tumor-suppressing role of IL-17 (18, 19) and
two studies reporting a tumor-promoting role of IL-17 via IL-6/
Stat3 signaling (20, 21). Most disturbingly, this profile of IL-17
activity was opposite even when examined in the context of var-
iants of the same B16 melanoma (19, 20).
To clarify whether IL-23-mediated tumor control was T-cell
specific and involved IL-17, we have assessed natural or cytokine-
induced innate immunity in several models of experimental
metastases and carcinogenesis. Clearly, IL-23 does very generally
and effectively suppress innate antitumor responses, though
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quite frequently, natural host immunity to tumors is not critically
dependent upon IL-17A.
Results
Host IL-23p19 Suppresses NK Cell-Mediated Control of Lung Meta-
stases.Experimentalmetastases of B16F10melanomawas initially
assessed by dose response in WT compared with IL-23p19−/−, IL-
12p40−/−, IL-12p35−/−, and IL-17A−/− mice (Fig. 1A and Fig. S1
A–C). As increasing doses were tested, there was a significantly
reduced level of B16F10 lung metastases in IL-23p19−/−mice and
a significantly increased level of B16F10 lung metastases in IL-
12p35−/−mice compared with WT and the other strains. The lack
of significant impact of the loss of IL-17A suggested host control of
B16F10 lung metastases was IL-17A independent. The com-
parative metastatic burden in WT and IL-12p40–deficient mice
suggested that loss of IL-12 countered the loss of IL-23 in p40-
deficient mice. Similar results were obtained with the B16 variant
(Fig. S2). By neutralizing IL-23p19 using mAb in WT and gene-
targeted mice, it was clear that the suppression of metastases in
the absence of IL-23 was independent of IL-17A, T, and B cells
(Fig. 1B). Importantly, blockade with anti-IL-12p40 increased
lung metastases in IL-23p19–deficient mice, and blockade with
anti-IL-23p19 or anti-IL-12p40 reduced lung metastases in IL-
12p35−/− mice (Fig. 1C). The data illustrated the antitumor
activity of IL-12 and the protumor activity of IL-23. By depleting
NK cells in WT or IL-23p19–deficient mice (with anti-asialoGM1
or anti-NK1.1), it was clear that host control of B16F10metastases
was NK cell dependent, but CD8+ T-cell independent (Fig. 1D).
Importantly, the equivalent levels of lung metastases between
anti-asialoGM1- or anti-NK1.1-treated WT and anti-asialoGM1-
or anti-NK1.1-treated IL-23p19–deficient mice suggested that the
activity of IL-23 was not independent of NK cells. A very similar
pattern of host IL-23p19 promotion of lung metastases was also
observed in RM-1 prostate carcinoma and 3LL lung carcinoma
models (Fig. S3), where NK cells have been shown to control
metastatic burden (22, 23), though IL-23p19, IL-12p40, and IL-
17A did not appear critical for MC38 colon adenocarcinoma
metastases (Fig. S2).
IL-2 Immunotherapy Is More Effective in the Absence of IL-23p19.We
have previously shown that early, high-dose IL-2 can substantially
reduce lung metastases in WT mice in a NK cell-, perforin (pfp),
and IFN-γ-dependentmanner (23); however, those studies did not
specifically evaluate the B16F10 tumor model. By using a very
high dose of B16F10 tumor cells, we showed that high-dose IL-2
significantly reduced B16F10 lung metastases in WTmice (47.6 ±
8.3 vs. 177.8 ± 7.3; P < 0.0079), and a comparable reduction in
metastases was observed in either IL-12p40– or IL-17A–deficient
mice (Fig. 2A). However, even more striking was the markedly
reduced metastases observed in IL-2–treated IL-23p19-deficient
mice (13.2± 3.1 vs. 144.4 ± 8.6; Fig. 2A). This greater suppression
of metastases in IL-23p19−/− mice was even more obvious when
dose was titered down from 100,000 to 10,000 U IL-2 (Fig. S4).
IL-23p19 Suppresses NK Cell-Mediated Control of Metastases by
Perforin and IFN-γ. IL-2-mediated suppression of B16F10 lung
metastases was NK cell dependent and CD8+T cell independent
in both WT and IL-23p19−/− mice, with IL-2 completely ineffec-
tive in either strain in the absence of NK cells (Fig. 2B). We next
examined the relative role of NK cell perforin and IFN-γ effector
mechanisms in IL-2-mediated control of B16F10 metastases. IL-2
was only partially effective in mice deficient for either perforin or
IFN-γ compared with WT or IL-23p19−/− mice (Fig. 2C). To de-
termine what role these effector molecules played in host control
of metastases in the absence of host IL-23p19, we generated mice
deficient in both IL-23p19 and perforin or IFN-γ. In the absence
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Fig. 1. Host IL-23p19 suppresses NK cell-mediated con-
trol of lung metastases. Groups of 5–15WT, IL-23p19−/−,
IL-12p40−/−, IL-12p35−/−, IL-17−/−, andRAG-1−/−micewere
injected i.v.witheither (A–C) 2×105or (D) 1×105B16F10
melanoma cells. In B and C, mice were additionally trea-
ted with control Ig (cIg), anti-IL-12p40 (α-p40), or anti-IL-
23p19 (α-p19) cells by treatment with antibodies (500 μg
i.p.) on day −1, 0, and 7 relative to tumor inoculation. In
D, micewere additionally depletedof CD8+ T cells (αCD8)
or NK (αASGM1 or αNK1.1) cells by treatment with anti-
bodies (100 μg i.p.) on day −1, 0, and 7 relative to tumor
inoculation. Fourteen days after tumor inoculation, the
lungs of these mice were harvested and fixed, and the
colonies counted and recorded for individual mice as
shown. Asterisks indicate the groups that are sig-
nificantly different fromuntreatedor cIg-treatedmice in
each strain. Mann–Whitney, *P < 0.05.
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of IL-23p19, perforin and IFN-γ collectively accounted for the IL-
2-mediated host response to B16F10, because only mice deficient
for both IL-23p19 and perforin and neutralized for IFN-γ using
mAb displayed a complete loss of IL-2 antimetastatic activity (Fig.
2D). The same qualitative result was obtained in the RM-1 tumor
model with IL-2 therapy (Fig. 2 E and F).
Carcinogen-Induced Tumors Are IL-23p19 Dependent.Only one study
has illustrated the ability of IL-23p19 to promote tumor initiation,
and this was in the context of DMBA/TPA-induced skin papil-
lomas (16). We confirmed these published results by comparing
papilloma incidence and number in C57BL/6 WTmice compared
with either IL-23p19−/− or IL-12p40−/− mice (Fig. 3). Similar to
reported by Langowski et al. (16), IL-23p19−/− mice were pro-
foundly resistant to DMBA/TPA-induced skin papilloma, with
less than 30% of mice developing lesions. Although IL-12p40−/−
were also resistant compared with WT mice, our data suggested
some balance existed between the levels of IL-12 and IL-23 in
controlling papilloma formation. Langowski et al. (16) showed
that IL-17 mRNA was barely detectable in the skin of DMBA/
TPA-treated IL-23p19–deficient and IL-12p40–deficient mice
compared with WT mice, but did not evaluate papilloma for-
mation in IL-17−/− mice. We found that IL-17A−/− mice were
resistant to DMBA/TPA-induced skin papilloma, but slightly
more susceptible than IL-23p19−/− mice (Fig. 3). These findings
suggest that IL-23p19 may only in part promote skin papilloma
formation via IL-17A, and that other IL-17A-independent factors
must contribute to this process.
Although IL-23p19 appeared critical in epithelial tumori-
genesis, the DMBA/TPA model is well recognized as a mouse
model of inflammation-induced cancer (24). Therefore, we
wished to determine the importance of IL-23p19 in the MCA
induction of fibrosarcoma model where host immunity has been
demonstrated as a critical factor in suppressing tumor initiation
(25, 26) and progression (27), and indeed innate NK and NKT
cells preventing the former (26, 28). Strikingly, even in this setting,
the loss of host IL-23p19 caused a profound reduction in the
initiation of fibrosarcomas byMCA (Fig. 4). Tumor incidence was
reduced at the highest dose and tumor onset was delayed at all
doses in IL-23p19−/− mice compared with WT mice. Similarly, a
reduction in tumor incidence was observed in WT mice neutral-
ized with an anti-IL-23p19mAb compared with those treated with
a control mAb (Fig. S5).When comparing this data with historical
data that we have generated in the samemodel (25), it is clear that
IL-23 is the most active host immune tumor-promoting factor we
have observed thus far. Interestingly, in this carcinogenesis model,
mice lacking either IL-12p40 or IL-17A displayed a similar tumor
incidence compared with WT mice (Fig. S6)—a result clearly
distinct from the DMBA/TPA model. This data first suggested
that loss of IL-12 is dominant over loss of IL-23 activity in this
mouse model of cancer, and second, in this context, that IL-23
action is independent of IL-17A. To further determine what cell
type was preventing tumor initiation in the absence of IL-23p19,
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Fig. 2. Host IL-23p19 suppresses IL-2 therapy of tumor meta-
stases. Groups of 5–15 WT, IL-23p19−/−, IL-12p40−/−, IL-17−/−,
pfp−/−, IFN-γ−/−, IL-23p19−/−xpfp−/−, or IL-23p19−/−xIFN-γ−/−mice
were injected i.v.with either (A–D) 7.5× 105 B16F10melanoma
cells or (E and F) 2× 105 RM-1 tumor cells.Mice received PBS (−)
or 100,000 U IL-2 (+) i.p. on day -1 before tumor inoculation.
Some IL-23p19−/−xpfp−/− mice were additionally treated with
anti-IFN-γ mAb (100 μg i.p.) on days −1, 0, and 7 to neutralize
IFN-γ. Fourteendays after tumor inoculation, the lungsof these
mice were harvested and fixed, and the colonies counted and
recorded for individual mice as shown. Asterisks indicate the
groups that are significantly different from IL-2-treated WT
miceor IL-2–treated IL-23p19−/−mice (for those strainsonp19−/−
background). Mann–Whitney, *P < 0.05.
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we additionally examined MCA induction in IL-23p19−/− mice
depleted of either CD8+T cells orNK cells for 6 weeks afterMCA
inoculation (Fig. 5). Consistent with previously published work in
WT mice (28), depletion of NK cells, but not CD8+ T cells,
completely abolished the protective effect of IL-23p19 deficiency
(Fig. 5). These data, in concert with that in Figs. 1 and 2, indicate
that IL-23 can suppress the surveillance, antimetastatic, and
immunotherapeutic activity of NK cells independent of IL-
17A activity.
Discussion
This study illustrates that IL-23p19 can suppress tumor metastases
and initiation controlled by NK cell-mediated immunity. In par-
ticular, NK cell perforin and IFN-γ effector functions appear to be
suppressed by host IL-23p19, and suppression is independent of
host IL-17A. Much emphasis has been placed on the ability of
IL-23p19, IL-1, and IL-6 to regulate Th17 cell differentiation
(reviewed in ref. 4), but clearly from our studies it is clear that
IL-23p19 has tumor-promoting activities that are independent of
IL-17A itself. Several recent reports have contradictedone another
and our data herein with respect to the role of IL-17 in natural host
response to B16 melanoma variants (19, 20). Martin-Orozco et al.
(19) reported that B16F10 melanoma was far more metastatic in
IL-17A–deficient mice than WT mice, whereas Wang et al. (20)
demonstrated slower s.c. B16 tumor growth in IL-17A–deficient
mice compared with WT mice. Regardless of whether we were
examining lungmetastases or s.c. growth, we sawno critical role for
host IL-17A (Fig. 1 and Fig. S7). It is notable that the former study
used their ownmixed 129×C57BL/6 orC57BL/6 backcrossed (n=
6) strains of IL-17A-deficientmice comparedwith F1 andC57BL/6
WT controls, respectively (19). Given that NK cells are critical for
B16F10 clearance from the lung, and 129 have a completely unique
NK gene complex and weak NK cytotoxic activity compared with
the C57BL/6 strain, this aspect of the study byMartin-Orozco et al.
(19) is very complicated to interpret. We also have been unable to
reproduce another report of greatly enhanced s.c. and metastatic
tumorgrowthofMC38 in IL-17A-deficientmice (samemiceasused
herein; Fig. S2) (18). We do not dispute that IL-17A may be very
important in controlling tumors in the context of T-cell responses,
but the current literature is verymisleadingwith respect towhat role
IL-17A might play in controlling the natural, innate immune
response to tumors, and clearly IL-23p19 is far more important.
Only in the DMBA/TPA induction of papilloma model was
host IL-17A shown to play any key role, and even in this model it
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Fig. 3. IL-23p19 promotes the formation of DMBA/TPA-induced skin papil-
lomas. Groups of 15–30 femaleWT, IL-23p19−/−, IL-12p40−/−, and IL-17−/−mice
were injectedwith 25 μg DMBA, and 1week later, twice weekly with 4 μg TPA
for 20 weeks as described inMaterials and Methods. Mice were subsequently
monitored for skin papilloma development for 25 weeks (n = 15 mice/group).
Results are shown as (A) themean lesion number per mouse over time and (B)
percentage of mice in the group with papillomas over time. Significant dif-
ferences in mean lesion number per mouse were observed by the unpaired
Mann–WhitneyU test (*, gene-targeted vs. WT, P < 0.05; **, p19−/− vs. p17−/−,
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Fig. 4. IL-23p19 promotes the formation of MCA-induced fibrosarcomas.
Groups of 10–25 male WT and IL-23p19−/− mice as indicated were injected
with either 5, 25,100, or 400 μg MCA as described in Materials and Methods
and subsequently monitored for tumor development over 300 days (pro-
portion of mice with tumors in each group shown in each panel). Mice were
injected with 400 μg MCA (A and B), 100 μg (C and D), 25 μg (E and F), or 5 μg
(G and H). Results are shown as the growth curves of individual mice with
sarcoma in each group after MCA inoculation. Proportion of mice develop-
ing lethal tumors is shown on right of each panel. Statistical differences in
tumor-free mice as determined by Fisher’s exact test: (A and B) WT vs. p19−/−
(P = 0.0009); (C and D) WT vs. p19−/− (P = 0.2443); (E and F) WT vs. p19−/−
(0.6614); and (H and I) WT vs. p19−/− (0.4737).
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did not account for all of the antitumor activity of IL-23p19. IL-
23p19 had previously been shown to promote tumor incidence and
growth in the DMBA/TPA model (16). Although others had
demonstrated that γδ+T cells and NKG2D activation receptor
were primarily responsible for preventing DMBA/TPA-induced
skin papilloma (29, 30), Langowski et al. (16) demonstrated some
evidence to suggest that IL-23p19 promoted tumor initiation by
suppressing CD8+ T-cell infiltration early after carcinogen
application. The key experiment to deplete either γδ+ T cells or
CD8+ T cells in IL-23p19–deficient mice treated with DMBA/
TPA remains to be performed, but it is clear from our work that
IL-23p19 does promote MCA-induced fibrosarcoma, by sup-
pressing the activity of NK cells rather than CD8+ T cells. It is
likely that the impact of IL-23 on different effector lymphocyte
populations (innate and adaptive) may be very model dependent.
The molecular mechanism by which IL-23 might suppress NK
cell effector functions, and whether this suppression is direct or
indirect, remains unclear. Most simplistically, IL-23p19 deficiency
may simply allow greater IL-12p70 formation that can then
stimulate the effective IFNγ production and cytotoxicity by NK
cells. Blockade of IL-12p40 in IL-23p19–deficient mice increased
tumor metastases, so clearly IL-12 is effective in suppressing
tumor formation in IL-23–deficient mice. However, a direct or
indirect tumor-promoting effect of IL-23 cannot be ruled out.
Despite a report of IL-23 protein expressed in tumor-associated
macrophages (TAM) (17), the means to use intracellular staining
to accurately determine which subsets of host cells make IL-23p19
remain limited. Our metastases data suggested that IL-23p19 was
suppressive in the absence of T andB cells, implying the possibility
that NK cells, myeloid cells, and tumor cells might act in concert.
Using a GFP reporter mouse, small populations of CD11b mye-
loid cells or CD11cDC, but not NK cells, reportedly constitutively
express the IL-23R (31), but our attempts to stain mouse IL-23R
on the surface of all cell types (including tumors) by flow cytom-
etry were unsuccessful. Thus, establishing whether TAM IL-23p19
acts indirectly via small populations of other myeloid cells or
tumors will require better reagents and further study. Though
IL-23 activities were evidently independent of IL-17, another
cytokinemade by the Th17 lineage, IL-22, is also produced by cells
of the innate immune system. A subset of mucosal NK cells
express IL-22 in response to IL-23, and unlike conventionally
described NK cells, these do not express high levels of IFN-γ or
cytotoxicity (32). Future experiments need to evaluate the role of
IL-22 and whether IL-23 serves to promote the numbers or
function of some innate NK cell subsets over others.
In all mouse tumor models, the loss of endogenous IL-12p35
activity resulted in more tumor formation, and the loss of host IL-
23p19 fewer tumors (ref. 16 and herein). The comparison of two
different models of tumor initiation (MCA fibrosarcoma and
DMBA/TPA skin) now demonstrates that the balance between
IL-12 and IL-23 activity can be quite distinct depending upon the
model examined. Additionally, the neutralization of host IFN-γ
has been reported to be tumor suppressive (33) or promoting (34).
Thus, the use of therapeutic strategies to enhance IL-12 activity
and abrogate IL-23 activity must consider these potential differ-
ences in tumor microenvironment. Despite a report that patients
with defects in IL-12Rβ1 or IL-12p40 have NK cells defective in
IFN-γ production (35), our study of the NK cell homeostasis
indicates that IL-23p19−/− mice have normal numbers and pro-
portions of all of the mature NK cell subsets (Fig. S8). The reve-
lation that IL-2 therapy was superior in IL-23p19–deficient hosts,
and independent of IL-17, suggests clearly that anti-human
IL-23p19 mAbs may be of great value in improving the current
clinical use of IL-2 in a variety of human cancer patients. It is
possible, although it remains to be formally tested, that other
therapies for cancer may also be more effective with IL-23p19
neutralization. Notably, though we have illustrated an important
tumor-promoting activity of host IL-23, studies in mice where
IL-23 has been administered systemically, or ectopically delivered
in the context of tumors or other cellular vehicles, have indicated
IL-23 can enhance antitumor immunity and suppress tumor
growth (36–40). Thus host and exogenous/therapeutic IL-23 may
be very distinct entities.With anti-human p19 and anti-human p40
mAbs in the clinic for the treatment of psoriasis, we will have
potentially some of the most interesting trials in human cancer
immune surveillance in place.
Materials and Methods
Mice. Inbred wild-type C57B6/J (C57BL/6 WT), C57BL/6 IL-12p40–deficient (IL-
12p40−/−), C57BL/6 IL-12p35–deficient (IL-12p35−/−), C57BL/6 perforin-deficient
(pfp−/−), C57BL/6 IFN-γ–deficient (IFN-γ−/−), and C57BL/6 RAG-1-deficient (RAG-
1−/−) mice were bred and maintained at the Peter MacCallum Cancer Centre
(PeterMac) as described previously (34). The above C57BL/6 gene-targetedmice
were all backcrossed at least 10 generations to C57B6/J, except C57BL/6 pfp−/−
mice, whichwere derived using C57B6/J ES cells. C57BL/6 IL-23p19–deficient (IL-
23p19−/−) mice were backcrossed by speed congenics to C57B6/J (microsatellite
analysis confirmed the resultant line 99.99% C57B6/J) and obtained from
Schering–Plough BioPharma (12). C57BL/6 IL-17A–deficient (IL-17−/−) mice were
backcrossed nine generations to C57B6/J (41). The syngeneic backgroundof the
IL-12p40−/−, IL-23p19−/−, and IL-17−/− strains was confirmed by skin grafting
against C57BL/6WTcontrols (asdonoror recipients). C57BL6 IL-23p19−/−xpfp−/−
and IL-23p19−/− x IFN-γ−/−micewere generated by intercross of the appropriate
strains aboveat PeterMac.Mice6–12weeks of agewereused inall experiments
that were performed according to Peter Mac Animal Experimental Ethics
Committee guidelines.
Metastatic Tumor Models. To examine metastatic tumor growth, WT or gene-
targetedmicewere inoculated i.v.with increasing doses of B16F10melanoma,
3LL lung carcinoma, or RM-1 prostate carcinoma cells. Mice were monitored
and harvested, and lung metastases were quantified as described previously
(22, 23). Some mice were treated with control Ig (Mac-4) or anti-IFN-γ (H22,
kindly provided by Robert Schreiber, St. Louis), anti-CD8 (53.6.7), anti-NK1.1
(PK136), or anti-asialoGM1 (Wako Chemicals), as indicated in the legends, to
neutralize IFN-γ or deplete cell subsets as previously described (23, 27, 28, 42).
Anti-agp3 (cIg, 4D2), anti-IL-23p19 (16E5), and anti-IL-12p40 (C17.8) were all
grafted on the same murine IgG1 background and kindly provided by
AMGEN, Inc. To examine cytokine immunotherapy of metastases, some
groups of mice received either PBS or recombinant IL-2 (Chiron Corporation;
10,000–100,000 U i.p. on day −1 relative to tumor inoculation as indicated).
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Fig. 5. IL-23p19 suppression of NK cells promotes the formation of MCA-
induced fibrosarcomas. Groups of 14–15 male WT and IL-23p19−/− mice as
indicatedwere injectedwith 400 μgMCAasdescribed inMaterials andMethods
and subsequentlymonitored for tumor development over 300 days (proportion
of mice with tumors in each group shown). WT or IL-23p19−/−mice were addi-
tionally treatedwith control Ig (cIg) or depleted of CD8+ T cell orNK cells weekly
from the time of MCA inoculation to day 42. Results are shown as the growth
curves of individual mice with sarcoma in each group after MCA inoculation.
Statistical differences as determined by Fisher’s exact test: (A–D) p19−/− + cIg vs.
p19−/− + anti-CD8 (ns), p19−/− + cIg vs. p19−/− + anti-ASGM1 (P = 0.0027).
8332 | www.pnas.org/cgi/doi/10.1073/pnas.1003251107 Teng et al.
Carcinogenesis Models. MCA model. Groups of 10–25 male WT, IL-23p19−/−,
and IL-12p40−/−mice were inoculated s.c. in the hind flank with 5, 25, 100, or
400 μg of 3-methylcholanthrene (MCA; Sigma–Aldrich) in 0.1 mL of corn oil
as described (25). Some WT mice received control Ig or weekly depletion of
CD8+ T cells (53.6.7) or NK cells (anti-asialoGM1) from the time of MCA
inoculation to day 42 (100 μg i.p.). Development of fibrosarcomas was
monitored weekly over the course of 250 days. Tumors >3 mm in diameter
and demonstrating progressive growth were recorded as positive. Meas-
urements were made with a caliper square as the product of two perpen-
dicular diameters (cm2), and individual mice are represented.
DMBA/TPA tumor model. Two-stage chemical carcinogenesis by DMBA/TPA was
as reported (25). Initiation was accomplished by pipette application of 25 μg
of DMBA (Sigma) in acetone onto the shaved-back skin of groups of 11–15
8-week-old female mice. Promotion was performed twice weekly with 4 μg of
TPA (Sigma) fromweek 1 toweek 20.Micewere assessedweekly for papilloma
development for up to 30 weeks, and lesions were counted and measured.
Statistical Analysis. Significant differences in metastases or papillomas were
determined by a Mann–Whitney U test, and differences in tumor incidence
were determined by the Fisher’s exact test. Values of P < 0.05 were
considered significant.
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SI Materials and Methods
Metastatic Tumor Models. To examine metastatic tumor growth,
WT or gene-targeted mice were inoculated i.v. with various doses
of either B16 melanoma or MC38 colon adenocarcinoma cells.
Mice were monitored and harvested, and lung metastases were
quantified as previously described (1, 2), with mice injected with
MC38 harvested at day 28.
Flow Cytometry. Single-cell suspensions were prepared from
organs and depleted of erythrocytes by ammonium chloride lysis,
as described (3). Cells were stained with anti-NK1.1-PE (PK136),
-TCRαβ-PECy5.5 (H57-597), -CD27-APC (Lg.7F9), and -CD11b-
FITC (M1/70). All antibodies were from eBioscience. Dead cells
were excluded with fluorogold (1 mg/mL) (Sigma) in the final
wash. Cells were acquired on the LSR-II (BD Biosciences).
Analysis was performed using FlowJo (Treestar Software).
MCA Model. Groups of 10–25 maleWT or gene-targeted mice were
inoculated s.c. in thehindflankwith 400μgof 3-methylcholanthrene
in 0.1mLof corn oil. SomeWTmice received control Ig (anti-agp3)
or anti-IL-23 i.p. twice weekly from the time ofMCA inoculation to
day 30 (500 μg i.p.). Development of fibrosarcomas was monitored
weekly over the course of 250 days. Tumors >3 mm in diameter
and demonstrating progressive growth were recorded as positive.
Measurements were made with a caliper square as the product of
two perpendicular diameters (cm2), and individual mice are
represented.
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Fig. S1. Host IL-23p19 suppresses lung metastases. Groups of 5–15 WT, IL-23p19−/−, IL-12p40−/−, IL-12p35−/−, and IL-17−/− mice were injected i.v. with (A) 5 ×
104, (B) 1 × 105, or (C) 5 × 105 B16F10 melanoma cells. Fourteen days after tumor inoculation, the lungs of these mice were harvested and fixed, and the
colonies counted and recorded for individual mice as shown. Asterisks indicate the groups that are significantly different from untreated or cIg-treated WT
mice. Mann–Whitney, *P < 0.05.
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Fig. S2. Host IL-23p19 suppresses lung metastases. Groups of 5–10 WT, IL-23p19−/−, IL-12p40−/−, or IL-17−/−mice were injected i.v. with B16 melanoma cells (A)
1 × 105, (B) 5 × 105, or MC38 colon adenocarcinoma cells (C) 1 × 105. Fourteen (A and B) or 28 (C) days after tumor inoculation, the lungs of these mice were
harvested and fixed, and the colonies counted and recorded for individual mice as shown. Asterisks indicate the groups that are significantly different fromWT
mice. Mann–Whitney, *P < 0.05.
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Fig. S3. Host IL-23p19 suppresses lung metastases. Groups of five WT, IL-23p19−/−, IL-12p40−/−, or IL-17−/−mice were injected i.v. with either 3LL (5 × 105 or 2 ×
105) or RM-1 (5 × 104 or 1 × 104) tumor cells. Fourteen days after tumor inoculation, the lungs of these mice were harvested and fixed, and the colonies counted
and recorded for individual mice as shown. Asterisks indicate the groups that are significantly different from untreated or cIg-treated WT mice. Mann–
Whitney, *P < 0.05.
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Fig. S4. Host IL-23p19 suppresses IL-2 therapy of tumor metastases. Groups of five WT and IL-23p19−/−mice were injected i.v. with 7.5 × 105 B16F10 melanoma
cells. Mice received PBS (−) or 10,000–100,000 U IL-2 as indicated i.p. on day −1 before tumor inoculation. Fourteen days after tumor inoculation, the lungs of
these mice were harvested and fixed, and the colonies counted and recorded for individual mice as shown. Asterisks indicate the groups that are significantly
different from IL-2–treated WT mice. Mann–Whitney, *P < 0.05.
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Fig. S5. IL-23p19 promotes the formation of MCA-induced fibrosarcomas. Groups of 15 male WT mice were inoculated s.c. in the hind flank with 400 μg of 3-
methylcholanthrene in 0.1 mL of corn oil. WT mice received either control Ig (anti-agp3) or anti-IL-23 i.p. on day −1, 0, 4, 7, 11, 14, 17, 22, 25, and 30 relative to
the time of MCA inoculation (day 0; 500 μg i.p.). (A) Percent survival of each group is depicted, and tumor growth (cm2) in individual mice is shown for control
anti-agp3 (B) and anti-IL-23 mAb (C).
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Fig. S6. IL-17 and IL-12 do not promote the formation of MCA-induced fibrosarcomas. Groups of 10–25 male IL-17−/− and IL-12p40−/− and IL-17−/− mice as
indicated were injected with either 5, 25,100, or 400 μg MCA as described inMaterials and Methods and subsequently monitored for tumor development over
300 days (proportion of mice with tumors in each group shown in each panel). Mice injected with 400 μg MCA (A and B), 100 μg (C and D), 25 μg (E and F), or
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Fig. S7. Host IL-23p19 suppresses B16F10 s.c. growth. Groups of five WT, IL-23p19−/−, IL-12p40−/−, or IL-17−/−mice were injected s.c. with 1 × 105 B16F10 tumor
cells. Tumor measurements were made periodically with a caliper square and recorded as the product of two perpendicular diameters (cm2). The mean ± SEM is
represented, and asterisks indicate the groups that are significantly different from WT mice. Mann–Whitney, *P < 0.05.
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Fig. S8. NK cell phenotype in IL-23p19−/− mice. Spleen, liver, lungs, bone marrow, and lymph node from B6 WT and IL-23p19−/− (p19−/−) mice were processed
for FACS analysis of NK cell subsets as described previously. NK cells (NK1.1+ TCRαβ−) are present in similar percentages in WT and p19−/− mice and exhibit
similar NK cell subsets (as determined by CD27 and CD11b) in p19−/− mice. Data shown are representative of three mice per group.
5 μg (G and H). Results are shown as the growth curves of individual mice with sarcoma in each group after MCA inoculation. Proportion of mice developing
lethal tumors is shown on right of each panel. Statistical differences in proportion tumor free with WT mice from Fig. 4 as determined by Fisher’s exact test: (A
and B) WT vs. p40−/− (ns), WT vs. IL-17−/− (ns); (C and D) WT vs. p40−/− (P = 0.1706), WT vs. IL-17−/− (P = 0.3444); (E and F) WT vs. p40−/− (P = 0.2262), WT vs. IL-17−/−
(0.6913); (G and H) WT vs. p40−/− (P = 0.2290), WT vs. IL-17−/− (P = 1.0000).
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